Cost–effectiveness of bemiparin in the prevention and treatment of venous thromboembolism

References

• Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest126(3 Suppl.), 338S–400S (2004).
   PubMed Web of Science ®Google Scholar
• Buller HR, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic therapy. Chest126(3 Suppl.), 401S–428S (2004).
   PubMedGoogle Scholar
• Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest126(3 Suppl.), 188S–203S (2004).
   PubMed Web of Science ®Google Scholar
• Matsagas MI. Outpatient treatment of venous thromboembolism using low molecular weight heparins. An overview. Int. Angiol.23(4), 305–316 (2004).
   PubMed Web of Science ®Google Scholar
• Planès A. Review on bemiparin sodium – a new second-generation low-molecular-weight heparin – and its applications in venous thromboembolism. Expert Opin. Pharmacother.4(9), 1551–1561 (2003).
   PubMed Web of Science ®Google Scholar
• Ascari E, Siragusa S, Piovella F. The epidemiology of deep vein thrombosis and pulmonary embolism. Haematologica80(2 Suppl.), 36–41 (1995).
   Google Scholar
• Heit JA, Silverstein MD, Mohr DN et al. The epidemiology of venous thromboembolism in the community. Thromb. Haemost.86(1), 452–463 (2001).
   PubMed Web of Science ®Google Scholar
• Heit JA, Melton LJ III, Lohse CM et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin. Proc.76(11), 1102–1110 (2001).
   PubMed Web of Science ®Google Scholar
• Anderson FA Jr, Wheeler HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch. Intern. Med.151(5), 933–938 (1991).
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann. Intern. Med.125, 1–7 (1996).
   Google Scholar
• Pengo V, Lensing AW, Prins MH et al. Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med.350(22), 2257–2264 (2004).
   PubMed Web of Science ®Google Scholar
• Ribeiro A, Lindmarker P, Johnsson H, Juhlin-Dannfelt A, Jorfeldt L. Pulmonary embolism: one-year follow-up with echocardiography doppler and five-year survival analysis. Circulation99, 1325–1330 (1999).
   PubMed Web of Science ®Google Scholar
• Schafer AI. Venous thrombosis as a chronic disease. N. Engl. J. Med.340(12), 955–956 (1999).
   Google Scholar
• Falkon L, Sáenz-Campos D, Antonijoan R, Martín S, Barbanoj M, Fontcuberta J. Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11). A three way cross-over study in healthy volunteers. Thromb. Res.78(1), 77–86 (1995).
   Google Scholar
• Falkon L, Bayés M, Frontera G, Garí M, Barbanoj M, Fontcuberta J. Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers – a dose-finding study within the therapeutical range. Thromb. Haemost.77(1), 133–136 (1997).
   PubMed Web of Science ®Google Scholar
• Racine E. Differentiation of the low-molecular-weight heparins. Pharmacotherapy21(Suppl. 2), 62S–70S (2001).
   PubMed Web of Science ®Google Scholar
• Fraxiparine® package insert. Sanofi-Synthélabo Canada Inc., Markham, Ontario (2001).
   Google Scholar
• Lovenox® package insert. Aventis Pharmaceuticals Products Inc., NJ, USA (2001).
   Google Scholar
• Fragmin® package insert. Pharmacia & Upjohn Company, MI, USA (2001).
   Google Scholar
• Innohep® package insert. DuPont Pharma, DE, USA (2001).
   Google Scholar
• Borrell M, Antonijoan RM, Ortín R et al. Pharmacokinetic profiles of two LMWH: bemiparin 3,500 IU and enoxaparin 4,000 IU after subcutaneous administration in healthy volunteers. Thromb. Haemost.86(Suppl.), CD3578 (2001) (Abstract).
   Google Scholar
• Depasse F, González de Suso MJ, Lagoutte I, Fontcuberta J, Borrell M, Samama MM. Comparative study of the pharmacokinetic profiles of two LMWHs – bemiparin (3,500 IU anti-Xa) and tinzaparin (4,500 IU anti-Xa) – administered subcutaneously to healthy male volunteers. Thromb. Res.109(2–3), 109–117 (2003).
   PubMed Web of Science ®Google Scholar
• Gebska MA, Titley I, Paterson HF et al. High-affinity binding sites for heparin generated on leukocytes during apoptosis arise from nuclear structures segregated during cell death. Blood99(6), 2221–2227 (2002).
   Google Scholar
• Morita S, Gebska MA, Kakkar AK, Scully MF. High affinity binding of heparin by necrotic tumour cells neutralises anticoagulant activity – implications for cancer related thromboembolism and heparin therapy. Thromb. Haemost.86(2), 616–622 (2001).
   PubMed Web of Science ®Google Scholar
• Falkon L, Gari M, Barbanoj M, Amiral J, Fontcuberta J. Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, bemiparin, at therapeutic subcutaneous doses. Blood Coagul. Fibrinolysis9(2), 137–141 (1998).
   PubMed Web of Science ®Google Scholar
• Valentin S, Ostergaard P, Kristensen H, Norfang O. Synergism between full length TFPI and heparin. Blood Coagul. Fibrinolysis3(2), 221–222 (1992).
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz A, Montes R, Carrasco P, Rocha E. Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin on hemostatic properties of endothelium. Clin. Appl. Thromb. Hemost.8(1), 65–71 (2002).
   PubMed Web of Science ®Google Scholar
• Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am. J. Cardiol.82(5B), 3L–10L (1998).
   PubMed Web of Science ®Google Scholar
• Cánovas M, De Luna M, Basi N, López-Belmonte L. RO-11, a new low molecular weight heparin. Proceedings of Advances in Anticoagulant, Antithrombotic and Thrombolytic Drugs. MA, USA (1992).
   Google Scholar
• Kakkar VV, Howes J, Sharma V, Kadziola Z. A comparative, double-blind, randomized trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment Group. Thromb. Haemost.83(4), 523–529 (2000).
   PubMedGoogle Scholar
• Planès A, Vochelle N, González de Suso MJ, Claracq JP. Prophylactic antithrombotic therapy after orthopaedic surgery using bemiparin, a second-generation low molecular weight heparin. Rev. Anestesiol. Reanim.48(6), 258–263 (2001). [Article in Spanish].
   Google Scholar
• Navarro-Quilis A, Castellet E, Rocha E, Paz-Jiménez J, Planès A. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty. A randomized double-blind clinical trial. J. Thromb. Haemost.1(3), 425–432 (2003).
   PubMedGoogle Scholar
• Abad JI, Gómez-Outes A, Martínez-González J, Maeso R, Rocha E. Observational study of bemiparin, first dose administered 6 hours after surgery, in hip or knee replacement surgery. Pathophysiol. Haemost. Thromb.33(Suppl. 2), 73 (2003) (Abstract).
   Google Scholar
• Fenollosa J, Seminario P. Efficacy and safety of bemiparin in the prophylaxis of venous thromboembolism in orthopedic surgery. Rev. Ortop. Traumatol.6, 460–465 (2001) [Article in Spanish].
   Google Scholar
• Otero-Fernández R, Gómez-Outes A, Martínez-González J, Maeso R, Fontcuberta J. Evaluation of the effectiveness and safety of bemiparin, a second-generation low-molecular-weight heparin, in several orthopaedic settings. Pathophysiol. Haemost. Thromb.33(Suppl. 2), 61 (2003) (Abstract).
   Google Scholar
• Bonal J, Gisbert R. Pharmacoeconomic analysis of the prophylaxis of venous thromboembolic disease in patients undergoing hip arthroplasty. Rev. Esp. Farmacoeconomía6(1), 17–26 (2000) [Article in Spanish].
   Google Scholar
• Moreno González E, Fontcuberta J, de la Llama F, EMRO (Grupo Estudio Multicéntrico RO-11). Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. Hepatogastroenterology43(9), 744–747 (1996).
   PubMedGoogle Scholar
• Hidalgo M, Figueroa JM. Prophylaxis of venous thromboembolism in abdominal wall surgery. Hernia4, 242–247 (2000).
   Google Scholar
• Gómez-Outes A, Martínez-González J, del Campo J, Rocha E. Optimal dosing of bemiparin for the prevention of venous thromboembolism in surgery for cancer. Pathophysiol. Haemost. Thromb.33(Suppl. 2), 78 (2003) (Abstract).
   Google Scholar
• Miras-Parra F, Navascués-Martínez E, Gómez-Outes A, Martínez-González J, Rocha E. Utilisation and safety of bemiparin, a low-molecular-weight heparin, in medical patients. A prospective, uncontrolled cohort study. Clin. Drug Invest.25(7), 463–472 (2005).
   PubMedGoogle Scholar
• Kakkar VV, Gebska M, Kadziola Z, Saba N, Carrasco P. Low-molecular-weight heparin in the acute and long-term treatment of deep-vein-thrombosis. Thromb. Haemost.89(4), 674–680 (2003).
   PubMed Web of Science ®Google Scholar
• Santamaría A, Juárez S, Reche A, Gómez-Outes A, Martínez-González J, Fontcuberta J. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA study. Int. J. Clin. Pract.60(5), 518–525 (2006).
   PubMedGoogle Scholar
• Rocha Hernando E, Soler Marín G, Rosario Díaz E, Pacho Rodríguez J, Monteagudo Ruíz, Martínez-González. Efectividad y seguridad de bemiparina en la prevención secundaria de la tromboembolia venosa: Un estudio prospectivo observacional. Haematologica (ed. Esp.)90(Suppl. 2), 135 (2005) (Abstract).
   Google Scholar
• Christidou FN, Frangia TK, Bamichas GI et al. Comparison of two low-molecular weight heparins (LMWHs), tinzaparin and bemiparin, during hemodialysis. Int. J. Clin. Pharmacol. Ther.43(7), 335–338 (2005).
   PubMedGoogle Scholar
• Horlocker TT, Wedel DJ, Benzon H et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg. Anesth. Pain Med.28(3), 172–197 (2003).
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, Maeso R, Moreno A, Martínez-González J. Safety and effectiveness of bemiparin during post-marketing surveillance studies for prevention of venous thromboembolism. Meth. Find. Exp. Clin. Pharmacol.26(Suppl. A), 155 (2004) (Abstract).
   Google Scholar
• Carlson MK, Gleason PP, Sen S. Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity. Pharmacotherapy21(1), 108–113 (2001).
   PubMed Web of Science ®Google Scholar
• Al-Mekhaizeem KA, Sherker AH. Heparin-induced hepatotoxicity. Can. J. Gastroenterol.15(8), 527–530 (2001).
   PubMedGoogle Scholar
• Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb. Haemost.71(1), 7–11 (1994).
   PubMed Web of Science ®Google Scholar
• Gheno G, Cinetto L, Savarino C et al. Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin. Eur. J. Clin. Pharmacol.59(5–6), 373–377 (2003).
   Google Scholar
• Rocha E, Gomez-Outes A, Martinez Gonzalez J, Kakkar VV. Effect of unfractionated heparin and long-term treatment with low-molecular-weight heparin, bemiparin, on potassium levels. Thromb. Haemost.94(5), 1109–1110 (2005).
   Google Scholar
• Honorato J, Gómez-Outes A, Navarro-Quilis A, Martínez-González J, Rocha E, Planès A. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. Pharmacoeconomics22(13), 885–894 (2004).
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, Rocha E, Martínez-González J, Kakkar VV. Cost–effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis. Pharmacoeconomics24(1), 81–92 (2006).
   PubMedGoogle Scholar
• Chapman TM, Goa KL. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis. Drugs63(21), 2357–2377 (2003).
   PubMedGoogle Scholar
• Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Arch. Orthop. Trauma Surg.124(8), 507–517 (2004).
   PubMed Web of Science ®Google Scholar
• Dahl OE, Pleil AM. Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement. J. Thromb. Haemost.1(5), 896–906 (2003).
   PubMed Web of Science ®Google Scholar
• Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low molecular weight heparins compared to unfractionated heparin for treatment of acute deep vein thrombosis. A cost–effectiveness analysis. Ann Intern. Med.130(10), 789–799 (1999).
   PubMedGoogle Scholar
• Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost–effectiveness analysis. Am. J. Med.111(2), 130–139 (2001).
   PubMed Web of Science ®Google Scholar
• Aujesky D, Smith KJ, Cornuz J, Roberts MS. Cost–effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism. Thromb. Haemost.93(3), 592–599 (2005).
   PubMed Web of Science ®Google Scholar
• van der Heijden JF, Hutten BA, Buller HR et al. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst. Rev.1, CD002001 (2002).
   Google Scholar
• Maddineni J, Walenga J, Jeske W, Hoppensteadt D, Fareed J, Messmore H. Therapeutic implications of product individuality in commercially available low molecular weight heparins and their generic versions. Pathophysiol. Haemost. Thromb.33(Suppl. 2), 61 (2003) (Abstract).
   Google Scholar
• Fareed J, Leong WL, Hoppensteadt DA et al. Generic low-molecular-weight heparins: some practical considerations. Semin. Thromb. Hemost.30(6), 703–713 (2004).
   PubMed Web of Science ®Google Scholar
• Prandoni P. Emerging strategies for treatment of venous thromboembolism. Expert Opin. Emerg. Drugs10(1), 87–94 (2005).
   PubMedGoogle Scholar
• Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med.162(16), 1833–1840 (2002).
   PubMed Web of Science ®Google Scholar
• Weitz JI, Bates SM. New anticoagulants. J. Thromb. Haemost.3(8), 1843–1853 (2005).
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther.78(4), 412–421 (2005).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Fisher WD, Bauer KA et al. BAY 59–7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J. Thromb. Haemost.3(11), 2479–2486 (2005).
   Google Scholar
• Eriksson BI, Borris L, Dahl OE et al.; ODIXa-HIP Study Investigators. Oral, direct factor Xa inhibition with BAY 59–7939 for the prevention of venous thromboembolism after total hip replacement. J. Thromb. Haemost.4(1), 121–128 (2006).
   PubMed Web of Science ®Google Scholar
• Gulseth MP. Ximelagatran: an orally active direct thrombin inhibitor. Am. J. Health Syst. Pharm.62(14), 1451–1467 (2005).
   Google Scholar
• Kam PC, Kaur N, Thong CL. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia60(6), 565–574 (2005).
   Google Scholar
• Eriksson BI, Dahl OE, Buller HR et al.; BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J. Thromb. Haemost.3(1), 103–111 (2005).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Ahnfelt L et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J. Thromb. Haemost.2(9), 1573–1580 (2004).
   PubMed Web of Science ®Google Scholar
• Weitz JI. New anticoagulants for treatment of venous thromboembolism. Circulation110(Suppl. 1), I19–I26 (2004).
   PubMed Web of Science ®Google Scholar